Jazz Pharmaceuticals plc (JAZZ) fair value analysis
Nasdaq · Updated 2026-10-19
JAZZ price how computed
Forward Fair Value verdict
Fairly valuedJAZZ is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $210.23
- Sector
- Healthcare
- 12-month range
- $131.16–$261.62
- Market cap
- $13.6B
- From 52-week high
- -19.6%
- Shares outstanding
- 64.9M
- Rank in Healthcare by discount to fair value
- #45 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Jazz Pharmaceuticals plc is a biopharmaceutical company that develops, manufactures, and commercializes medicines for patients with serious conditions across various therapeutic areas including neuroscience, oncology, and other specialized areas. The company operates globally with research, development, and commercial operations across multiple countries including the United States, Europe, and other international markets.
JAZZ currently ranks #45 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $13.6B
- P/E (trailing)
- 8x
- Revenue (TTM)
- $4.6B
- Net margin
- 20.4%
- EPS (TTM)
- $24.86
- Gross margin
- 90.4%
- Debt / equity
- 0.92
- Revenue growth (3-yr avg)
- 8.1%
- Shares outstanding
- 64.9M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 23 · oversold
- 50-day average
- $239.94
- 200-day average
- $214.47
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-3.4%)
2026-03 ▲ beat (+36.1%)
2025-12 ▲ beat (+2.1%)
2025-09 ▲ beat (+45.6%)
2025-06 ▼ miss (-32.0%)
2025-03 ▼ miss (-63.9%)
2024-12 ▲ beat (+13.6%)
2024-09 ▲ beat (+20.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 20 buy · 2 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $295
- Target vs last price
- +40.3%
What our data shows for JAZZ
- Our model validated 17 trailing price-to-earnings windows for JAZZ, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $131.16–$261.62.
- The 14-day relative strength index sits at an oversold 23.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for JAZZ
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent JAZZ news
TickrTrends' derived news-sentiment signal for JAZZ is currently leaning positive, computed from recent coverage.
- JAZZ Maintains Overweight Rating -- Price Target Lowered to $314 (gurufocus.com, 2026-10-21)
TickrTrends take: Jazz Pharmaceuticals maintains an overweight rating from analysts despite a price target reduction to 314, suggesting the market still views the company as having upside potential despite recent valuation adjustments. Given TickrTrends' assessment that JAZZ is fairly valued, the lowered price target indicates analyst expectations may have shifted on growth or earnings assumptions rather than a fundamental revaluation of the company's standing. Investors focused on valuation metrics should monitor whether this rating change reflects sector-wide Healthcare pressures or company-specific factors that could affect fair value assessments going forward. - Jazz Pharmaceuticals PLC (JAZZ) Director Bruce Cozadd Sells 6,000 Shares (gurufocus.com, 2026-10-05)
TickrTrends take: Jazz Pharmaceuticals is currently assessed as fairly valued by TickrTrends, suggesting the market price aligns reasonably with fundamental metrics in the Healthcare sector. Recent insider selling activity, such as Director Bruce Cozadd's disposition of shares, warrants monitoring to determine whether such transactions reflect confidence constraints or routine portfolio management, particularly as valuation multiples remain in equilibrium. Investors should track patterns in insider transactions alongside any changes to the company's operational performance or sector dynamics that could shift the fairly valued assessment. - JAZZ Initiates Coverage On Citigroup -- Price Target Set at $325 (gurufocus.com, 2026-09-30)
TickrTrends take: JAZZ has received analyst coverage initiation from Citigroup with a price target of $325, which provides an external valuation benchmark for investors to assess against the current market price. Given TickrTrends' assessment that JAZZ is fairly valued, this new price target represents a specific milestone that valuation-focused investors should monitor to determine if it signals potential upside or reflects consensus expectations already embedded in the stock's price. In the Healthcare sector context, this coverage initiation adds to the analyst visibility on the company and could influence how the market reprices the stock relative to its fundamental value.
More JAZZ news
- JAZZ Reinstated by Goldman Sachs -- Price Target Set at $337 (gurufocus.com, 2026-09-24)
What people are saying
Follow the JAZZ conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — JAZZ's technical positioning shifted this week as its Relative Strength Index moved from neutral into oversold territory, suggesting the stock has experienced sharp recent selling pressure. The company's sector discount rank improved to #62 from #72, indicating it now trades at a smaller discount relative to other Healthcare sector companies. Despite these technical changes, JAZZ maintains a Fairly valued assessment based on current valuation metrics.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is JAZZ stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), JAZZ is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is JAZZ's TickrTrends verdict?
JAZZ's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does JAZZ compare to other Healthcare stocks?
JAZZ ranks #45 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is JAZZ overbought or oversold?
JAZZ's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does JAZZ report earnings next?
JAZZ's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does JAZZ usually beat earnings estimates?
Over its last 8 reported quarters JAZZ beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about JAZZ?
Of 22 analysts covering JAZZ, 20 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $295 (+40.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
JAZZ vs BAX · JAZZ vs ENSG · JAZZ vs EXEL · JAZZ vs HSIC · JAZZ vs INVA